303 related articles for article (PubMed ID: 36291766)
1. Targeting KRAS in PDAC: A New Way to Cure It?
He Q; Liu Z; Wang J
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291766
[TBL] [Abstract][Full Text] [Related]
2. Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.
Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
[TBL] [Abstract][Full Text] [Related]
3. A Breakthrough Brought about by Targeting KRAS
Ning W; Yang Z; Kocher GJ; Dorn P; Peng RW
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053550
[TBL] [Abstract][Full Text] [Related]
4. Glimmers of hope for targeting oncogenic KRAS-G12D.
Tang D; Kang R
Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
[TBL] [Abstract][Full Text] [Related]
5. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Bannoura SF; Khan HY; Azmi AS
Front Oncol; 2022; 12():1013902. PubMed ID: 36531078
[TBL] [Abstract][Full Text] [Related]
6. KRAS inhibition activates an actionable CD24 'don't eat me' signal in pancreas cancer.
Wei Y; Liu M; Yen EY; Yao J; Nguyen PT; Wang X; Yang Z; Yousef A; Pan D; Jin Y; Theady MS; Park J; Cai Y; Takeda M; Vasquez M; Zhou Y; Zhao H; Viale A; Wang H; Zhao D; DePinho RA; Yao W; Ying H
bioRxiv; 2023 Sep; ():. PubMed ID: 37790498
[TBL] [Abstract][Full Text] [Related]
7. Covalent inhibitor targets KRas
Li HY; Qi WL; Wang YX; Meng LH
Genes Dis; 2023 Mar; 10(2):403-414. PubMed ID: 37223497
[No Abstract] [Full Text] [Related]
8. Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma.
Ramalingam PS; Priyadharshini A; Emerson IA; Arumugam S
Front Med (Lausanne); 2023; 10():1107128. PubMed ID: 37396909
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer.
Qunaj L; May MS; Neugut AI; Herzberg BO
Front Oncol; 2023; 13():1252516. PubMed ID: 37790760
[No Abstract] [Full Text] [Related]
10. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.
Naim N; Moukheiber S; Daou S; Kourie HR
Crit Rev Oncol Hematol; 2021 Dec; 168():103524. PubMed ID: 34800654
[TBL] [Abstract][Full Text] [Related]
11. Modeling receptor flexibility in the structure-based design of KRAS
Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B
J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206
[TBL] [Abstract][Full Text] [Related]
12. Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure.
de Jesus VHF; Mathias-Machado MC; de Farias JPF; Aruquipa MPS; Jácome AA; Peixoto RD
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894382
[TBL] [Abstract][Full Text] [Related]
13. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond.
Nagasaka M; Potugari B; Nguyen A; Sukari A; Azmi AS; Ou SI
Cancer Treat Rev; 2021 Dec; 101():102309. PubMed ID: 34715449
[TBL] [Abstract][Full Text] [Related]
14. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
15. KRAS G12C fragment screening renders new binding pockets.
Mathieu M; Steier V; Fassy F; Delorme C; Papin D; Genet B; Duffieux F; Bertrand T; Delarbre L; Le-Borgne H; Parent A; Didier P; Marquette JP; Lowinski M; Houtmann J; Lamberton A; Debussche L; Alexey R
Small GTPases; 2022 Jan; 13(1):225-238. PubMed ID: 34558391
[TBL] [Abstract][Full Text] [Related]
16. The Therapeutic Landscape for
Tria SM; Burge ME; Whitehall VLJ
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190303
[TBL] [Abstract][Full Text] [Related]
17. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
18. Targeting KRAS in Non-Small Cell Lung Cancer.
Corral de la Fuente E; Olmedo Garcia ME; Gomez Rueda A; Lage Y; Garrido P
Front Oncol; 2021; 11():792635. PubMed ID: 35083149
[TBL] [Abstract][Full Text] [Related]
19. Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors.
Indini A; Rijavec E; Ghidini M; Cortellini A; Grossi F
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34064352
[TBL] [Abstract][Full Text] [Related]
20. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
